Pazopanib vs pazopanib plus gemcitabine in refractory soft tissue sarcoma: A randomized phase II trial of the AIO.

HJ Schmoll; J Russel; P Reichardt; L Lindner; HG Kopp; A Stein; F Cygon; K Heissner

doi:10.1200/JCO.2016.34.15_suppl.11004

Pazopanib vs pazopanib plus gemcitabine in refractory soft tissue sarcoma: A randomized phase II trial of the AIO.

HJ Schmoll
, J Russel
, P Reichardt
, L Lindner
, HG Kopp
, A Stein
, F Cygon
, K Heissner

Department of Internal Medicine III, Division of Respiratory Medicine, Allergology and Sleep Medicine

Research output: Contribution to journal › Abstract (Journal) › peer-review

3 Citations (Web of Science)

Original language	English
Journal	JOURNAL OF CLINICAL ONCOLOGY
Volume	34
Issue number	15
DOIs	https://doi.org/10.1200/JCO.2016.34.15_suppl.11004
Publication status	Published - 2016
Event	Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) - Chicago, IL Duration: 3 Jun 2016 → 7 Jun 2016

Access to Document

10.1200/JCO.2016.34.15_suppl.11004

Cite this

Schmoll, HJ., Russel, J., Reichardt, P., Lindner, L., Kopp, HG., Stein, A., Cygon, F., & Heissner, K. (2016). Pazopanib vs pazopanib plus gemcitabine in refractory soft tissue sarcoma: A randomized phase II trial of the AIO. JOURNAL OF CLINICAL ONCOLOGY , 34(15). https://doi.org/10.1200/JCO.2016.34.15_suppl.11004

Schmoll, HJ ; Russel, J ; Reichardt, P et al. / Pazopanib vs pazopanib plus gemcitabine in refractory soft tissue sarcoma: A randomized phase II trial of the AIO. In: JOURNAL OF CLINICAL ONCOLOGY 2016 ; Vol. 34, No. 15.

@article{ce0e810ac80e4c678720f23da1033e2e,

title = "Pazopanib vs pazopanib plus gemcitabine in refractory soft tissue sarcoma: A randomized phase II trial of the AIO.",

author = "HJ Schmoll and J Russel and P Reichardt and L Lindner and HG Kopp and A Stein and F Cygon and K Heissner",

year = "2016",

doi = "10.1200/JCO.2016.34.15\_suppl.11004",

language = "English",

volume = "34",

journal = "JOURNAL OF CLINICAL ONCOLOGY ",

issn = "0732-183X",

publisher = "Lippincott Williams \& Wilkins ",

number = "15",

note = "Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) ; Conference date: 03-06-2016 Through 07-06-2016",

}

Schmoll, HJ, Russel, J, Reichardt, P, Lindner, L, Kopp, HG, Stein, A, Cygon, F & Heissner, K 2016, 'Pazopanib vs pazopanib plus gemcitabine in refractory soft tissue sarcoma: A randomized phase II trial of the AIO.', JOURNAL OF CLINICAL ONCOLOGY , vol. 34, no. 15. https://doi.org/10.1200/JCO.2016.34.15_suppl.11004

Pazopanib vs pazopanib plus gemcitabine in refractory soft tissue sarcoma: A randomized phase II trial of the AIO. / Schmoll, HJ; Russel, J; Reichardt, P et al.
In: JOURNAL OF CLINICAL ONCOLOGY , Vol. 34, No. 15, 2016.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Pazopanib vs pazopanib plus gemcitabine in refractory soft tissue sarcoma: A randomized phase II trial of the AIO.

AU - Schmoll, HJ

AU - Russel, J

AU - Reichardt, P

AU - Lindner, L

AU - Kopp, HG

AU - Stein, A

AU - Cygon, F

AU - Heissner, K

PY - 2016

Y1 - 2016

U2 - 10.1200/JCO.2016.34.15_suppl.11004

DO - 10.1200/JCO.2016.34.15_suppl.11004

M3 - Abstract (Journal)

SN - 0732-183X

VL - 34

JO - JOURNAL OF CLINICAL ONCOLOGY

JF - JOURNAL OF CLINICAL ONCOLOGY

IS - 15

T2 - Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Y2 - 3 June 2016 through 7 June 2016

ER -

Schmoll HJ, Russel J, Reichardt P, Lindner L, Kopp HG, Stein A et al. Pazopanib vs pazopanib plus gemcitabine in refractory soft tissue sarcoma: A randomized phase II trial of the AIO. JOURNAL OF CLINICAL ONCOLOGY . 2016;34(15). doi: 10.1200/JCO.2016.34.15_suppl.11004